These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18245492)

  • 1. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen.
    Lauwen MM; Zwaveling S; de Quartel L; Ferreira Mota SC; Grashorn JA; Melief CJ; van der Burg SH; Offringa R
    Cancer Res; 2008 Feb; 68(3):893-900. PubMed ID: 18245492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
    Zwaveling S; Vierboom MP; Ferreira Mota SC; Hendriks JA; Ooms ME; Sutmuller RP; Franken KL; Nijman HW; Ossendorp F; Van Der Burg SH; Offringa R; Melief CJ
    Cancer Res; 2002 Nov; 62(21):6187-93. PubMed ID: 12414646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
    Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
    J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
    Kuball J; Schuler M; Antunes Ferreira E; Herr W; Neumann M; Obenauer-Kutner L; Westreich L; Huber C; Wölfel T; Theobald M
    Gene Ther; 2002 Jul; 9(13):833-43. PubMed ID: 12080377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
    Vierboom MP; Zwaveling S; Bos GMJ ; Ooms M; Krietemeijer GM; Melief CJ; Offringa R
    Cancer Res; 2000 Oct; 60(19):5508-13. PubMed ID: 11034095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
    Chikamatsu K; Albers A; Stanson J; Kwok WW; Appella E; Whiteside TL; DeLeo AB
    Cancer Res; 2003 Jul; 63(13):3675-81. PubMed ID: 12839958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope.
    Kianizad K; Marshall LA; Grinshtein N; Bernard D; Margl R; Cheng S; Beermann F; Wan Y; Bramson J
    Cancer Res; 2007 Jul; 67(13):6459-67. PubMed ID: 17616707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses.
    Caserta S; Alessi P; Guarnerio J; Basso V; Mondino A
    Cancer Res; 2008 Apr; 68(8):3010-8. PubMed ID: 18413771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis.
    Erez-Alon N; Herkel J; Wolkowicz R; Ruiz PJ; Waisman A; Rotter V; Cohen IR
    Cancer Res; 1998 Dec; 58(23):5447-52. PubMed ID: 9850078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity.
    Steitz J; Brück J; Gambotto A; Knop J; Tüting T
    Gene Ther; 2002 Feb; 9(3):208-13. PubMed ID: 11859424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of DNA vaccine potency against legumain.
    Smahel M; Duskova M; Polakova I; Musil J
    J Immunother; 2014 Jun; 37(5):293-303. PubMed ID: 24810641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes.
    Steinaa L; Rasmussen PB; Rygaard J; Mouritsen S; Gautam A
    Scand J Immunol; 2007 Mar; 65(3):240-8. PubMed ID: 17309778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmunity and tumor immunity induced by immune responses to mutations in self.
    Engelhorn ME; Guevara-Patiño JA; Noffz G; Hooper AT; Lou O; Gold JS; Kappel BJ; Houghton AN
    Nat Med; 2006 Feb; 12(2):198-206. PubMed ID: 16444264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of p53 on anti-tumor immunity (review).
    Bueter M; Gasser M; Lebedeva T; Benichou G; Waaga-Gasser AM
    Int J Oncol; 2006 Feb; 28(2):519-25. PubMed ID: 16391808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.